(EWTX) Edgewise Therapeutics - Ratings and Ratios
Muscle, Disease, Drugs, Pipeline
EWTX EPS (Earnings per Share)
EWTX Revenue
Description: EWTX Edgewise Therapeutics August 13, 2025
Edgewise Therapeutics Inc (NASDAQ:EWTX) is a biotechnology company listed on the NASDAQ stock exchange. As a player in the biotechnology sub-industry, the companys primary focus is on developing innovative treatments, likely for rare or genetic disorders.
The stocks recent price action indicates a decline from its 52-week high of $36.62 to its current price of $12.99, representing a significant drop of approximately 65%. This volatility is reflected in the stocks average true range (ATR) of 5.54%, suggesting a relatively high level of price fluctuation. The low beta of 0.265 indicates that the stocks price movements are less correlated with the overall market, potentially making it a more stable investment during turbulent market conditions.
From a fundamental perspective, Edgewise Therapeutics has a market capitalization of $1.335 billion, indicating a moderate level of market presence. The absence of a price-to-earnings (P/E) ratio and forward P/E ratio suggests that the company is currently unprofitable, which is common for biotech companies that often require significant investment in research and development before generating revenue. The return on equity (ROE) of -30.95% further reinforces this, highlighting the companys current unprofitability.
Key performance indicators (KPIs) to monitor for Edgewise Therapeutics include the progress of its pipeline treatments, particularly any upcoming clinical trials or FDA approvals, which can significantly impact the stocks price. Additionally, investors should keep a close eye on the companys cash burn rate, as biotech companies often require substantial funding to support their research and development activities. The companys ability to secure future funding, either through equity or debt, will be crucial in determining its long-term viability.
Economic drivers that may influence Edgewise Therapeutics stock performance include overall market sentiment towards the biotechnology sector, advancements in related technologies, and the regulatory environment. The companys valuation will also be influenced by its ability to bring new treatments to market and achieve commercial success, which will be reflected in its revenue growth and profitability metrics.
EWTX Stock Overview
| Market Cap in USD | 1,587m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2021-03-26 |
EWTX Stock Ratings
| Growth Rating | -0.88% |
| Fundamental | 33.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -56.2% |
| Analyst Rating | 4.30 of 5 |
EWTX Dividends
Currently no dividends paidEWTX Growth Ratios
| Growth Correlation 3m | 81.4% |
| Growth Correlation 12m | -71.5% |
| Growth Correlation 5y | 12.2% |
| CAGR 5y | 24.33% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.35 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.82 |
| Sharpe Ratio 12m | -0.30 |
| Alpha | -55.36 |
| Beta | 0.292 |
| Volatility | 64.62% |
| Current Volume | 1224.4k |
| Average Volume 20d | 726.1k |
| Stop Loss | 17.1 (-6.5%) |
| Signal | -0.02 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-150.7m TTM) > 0 and > 6% of Revenue (6% = 127.1k TTM) |
| FCFTA -0.20 (>2.0%) and ΔFCFTA -0.79pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 27.5k% (prev 22.3k%; Δ 5193 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.20 (>3.0%) and CFO -124.8m > Net Income -150.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 28.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (104.9m) change vs 12m ago 12.22% (target <= -2.0% for YES) |
| Gross Margin -111.0% (prev 9.41%; Δ -120.5pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.37% (prev 0.42%; Δ -0.05pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -5.25 (EBITDA TTM -167.4m / Interest Expense TTM 24.1m) >= 6 (WARN >= 3) |
Altman Z'' -17.38
| (A) 0.95 = (Total Current Assets 603.3m - Total Current Liabilities 20.9m) / Total Assets 613.3m |
| (B) -0.74 = Retained Earnings (Balance) -455.5m / Total Assets 613.3m |
| (C) -0.22 = EBIT TTM -126.6m / Avg Total Assets 572.5m |
| (D) -18.76 = Book Value of Equity -455.3m / Total Liabilities 24.3m |
| Total Rating: -17.38 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 33.13
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -12.61% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.01 = 2.50 |
| 5. Debt/Ebitda 0.23 = 2.46 |
| 6. ROIC - WACC (= -32.82)% = -12.50 |
| 7. RoE -30.65% = -2.50 |
| 8. Rev. Trend 18.95% = 1.42 |
| 9. EPS Trend 35.08% = 1.75 |
What is the price of EWTX shares?
Over the past week, the price has changed by +14.04%, over one month by +21.87%, over three months by +34.31% and over the past year by -46.98%.
Is Edgewise Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EWTX is around 15.85 USD . This means that EWTX is currently overvalued and has a potential downside of -13.29%.
Is EWTX a buy, sell or hold?
- Strong Buy: 5
- Buy: 3
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the EWTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 36.2 | 97.8% |
| Analysts Target Price | 36.2 | 97.8% |
| ValueRay Target Price | 17.5 | -4.5% |
EWTX Fundamental Data Overview October 20, 2025
P/B = 2.6825
Beta = 0.292
Revenue TTM = 2.12m USD
EBIT TTM = -126.6m USD
EBITDA TTM = -167.4m USD
Long Term Debt = 4.37m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.00m USD (from shortTermDebt, last quarter)
Debt = 4.37m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -39.0m USD (from netDebt column, last quarter)
Enterprise Value = 996.9m USD (1.59b + Debt 4.37m - CCE 594.0m)
Interest Coverage Ratio = -5.25 (Ebit TTM -126.6m / Interest Expense TTM 24.1m)
FCF Yield = -12.61% (FCF TTM -125.7m / Enterprise Value 996.9m)
FCF Margin = -5933 % (FCF TTM -125.7m / Revenue TTM 2.12m)
Net Margin = -7115 % (Net Income TTM -150.7m / Revenue TTM 2.12m)
Gross Margin = -111.0% ((Revenue TTM 2.12m - Cost of Revenue TTM 4.47m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.63 (Enterprise Value 996.9m / Total Assets 613.3m)
Interest Expense / Debt = 71.08% (Interest Expense 3.11m / Debt 4.37m)
Taxrate = 0.00% (-1.0 / -133.8m)
NOPAT = -126.6m (EBIT -126.6m * (1 - 0.00%)) [loss with tax shield]
Current Ratio = 28.87 (Total Current Assets 603.3m / Total Current Liabilities 20.9m)
Debt / Equity = 0.01 (Debt 4.37m / totalStockholderEquity, last quarter 589.1m)
Debt / EBITDA = 0.23 (negative EBITDA) (Net Debt -39.0m / EBITDA -167.4m)
Debt / FCF = 0.31 (negative FCF - burning cash) (Net Debt -39.0m / FCF TTM -125.7m)
Total Stockholder Equity = 491.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -24.57% (Net Income -150.7m / Total Assets 613.3m)
RoE = -30.65% (Net Income TTM -150.7m / Total Stockholder Equity 491.7m)
RoCE = -25.52% (EBIT -126.6m / Capital Employed (Equity 491.7m + L.T.Debt 4.37m))
RoIC = -25.75% (negative operating profit) (NOPAT -126.6m / Invested Capital 491.7m)
WACC = 7.07% (E(1.59b)/V(1.59b) * Re(7.09%) + (debt cost/tax rate unavailable))
Discount Rate = 7.09% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 27.28%
Fair Price DCF = unknown (Cash Flow -125.7m)
EPS Correlation: 35.08 | EPS CAGR: 41.34% | SUE: 4.0 | # QB: 2
Revenue Correlation: 18.95 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
Additional Sources for EWTX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle